# Severe scleroderma colopathy at initial diagnosis of systemic sclerosis in a young man: a case report

**Authors:** Murad Isaak Alshamisti, Nouraldeen Deeb, Ahmad Almasalmah, Samer Amayre, Issa Abu Iram, Saed Ismael Atawnah, Mohammad Ibriwesh

PMC · DOI: 10.3389/fmed.2026.1784858 · Frontiers in Medicine · 2026-03-12

## TL;DR

A young man with systemic sclerosis experienced severe colon issues and weight loss, highlighting the importance of early diagnosis for this rare condition.

## Contribution

This case report presents a rare instance of severe scleroderma colopathy in a young male with systemic sclerosis.

## Key findings

- The patient showed extreme weight loss and chronic GI symptoms due to severe lower-GI dysmotility.
- Colonoscopy revealed marked colonic hypomotility with retained fecal matter.
- Treatment with mycophenolate mofetil and supportive therapy led to clinical improvement.

## Abstract

Scleroderma, or systemic sclerosis (SSc) usually affects the gastrointestinal (GI) tract (up to ~90%), but severe lower GI dysmotility and intestinal pseudo- obstruction are uncommon, occurring in approximately 5. 4% of patients with SSc. We report a 25-year-old Palestinian male with a three- year history of profound unintentional weight loss (67 kg) and an eight- month history of postprandial diffuse abdominal pain, bloating, vomiting, diarrhea, and loss of appetite. Examination revealed cachexia, digital ulcers, and generalized skin thickening with hyperpigmentation. Inflammatory markers were elevated (CRP/ESR) with positive antinuclear antibody. Upper endoscopy demonstrated severe reflux esophagitis extending to the upper esophagus and mild erosive gastritis of the antrum. Colonoscopy revealed marked colonic hypomotility with minimal peristalsis and retained fecal matter. The patient was treated with mycophenolate mofetil beside symptomatic and supportive therapy (rifaximin, hyoscine butylbromide, and metoclopramide), with clinical improvement on follow-up. This case highlights severe SSc- related lower- GI dysmotility in a young male with extreme weight loss and chronic GI symptoms. Clinicians should consider SSc in patients with unexplained dysmotility/pseudo-obstruction features, especially when associated with Raynaud- spectrum vascular features, skin thickening, or positive ANA to reduce diagnostic delay and prevent further consequences, such as malnutrition.

## Linked entities

- **Chemicals:** mycophenolate mofetil (PubChem CID 5281078), rifaximin (PubChem CID 6436173), hyoscine butylbromide (PubChem CID 6852391), metoclopramide (PubChem CID 4168)
- **Diseases:** systemic sclerosis (MONDO:0005100), scleroderma (MONDO:0005100)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** Raynaud (MESH:D011928), hyperpigmentation (MESH:D017495), reflux esophagitis (MESH:D005764), abdominal pain (MESH:D015746), ulcers (MESH:D014456), weight loss (MESH:D015431), GI dysmotility (MESH:D015154), symptoms (MESH:D012816), malnutrition (MESH:D044342), loss of appetite (MESH:D001068), diarrhea (MESH:D003967), intestinal pseudo- obstruction (MESH:D007418), colonic hypomotility (MESH:D003108), Inflammatory (MESH:D007249), SSc (MESH:D012595), cachexia (MESH:D002100), vomiting (MESH:D014839), gastritis (MESH:D005756)
- **Chemicals:** mycophenolate mofetil (MESH:D009173), rifaximin (MESH:D000078262), metoclopramide (MESH:D008787), hyoscine butylbromide (MESH:D002086)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13017854/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13017854/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC13017854/full.md

---
Source: https://tomesphere.com/paper/PMC13017854